Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Intracerebral Hemorrhage Leads to Anemia By Disrupting Erythropoiesis and Erythromyeloblastic Islands

Shijie Zhang, Peijun Jia, Qinfeng Peng, Jiaming Cao, Yuanlin Xu, Chao Jiang, Hongtao Ji, Fuyou Guo, Yan Li, Jingxin Zhang, Huan Zhang, Jiaxin Li, Ying Zhang, Xinyang Zhao, Xuemei Chen, Jian Wang, Xiuli An

Blood (2023) 142 (Supplement 1): 3821.

https://doi.org/10.1182/blood-2023-186235

Published: 2023

Journal Articles

The Impact of ZNF384 Rearranged on Antigen Editing during Treatment-Specific Selective Pressures in Adult B Cell Acute Lymphoid Leukemia

Runxia Gu, Wenbin Liu, Yihan Mei, Le Li, Chunlin Zhou, Yan Li, Yuntao Liu, Shuning Wei, Dong Lin, Kaiqi Liu, Qiuyun Fang, Xiaoyuan Gong, Benfa Gong, Shaowei Qiu, Bingcheng Liu, Yingchang Mi, Hui Wei, Ying Wang, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 4209.

https://doi.org/10.1182/blood-2023-188950

Published: 2023

Journal Articles

Prognostic Value of MRD By Flow Cytometry in Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Treated with Pediatric-Inspired Regimen: A Post-Hoc Analysis from a Prospective Study of China

Xiaoyuan Gong, Qiuyun Fang, Runxia Gu, Shaowei Qiu, Kaiqi Liu, Dong Lin, Chunlin Zhou, Guangji Zhang, Benfa Gong, Yuntao Liu, Yan Li, Shouyun Li, Bingcheng Liu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 6073.

https://doi.org/10.1182/blood-2023-174856

Published: 2023

Journal Articles

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Blood (2023) 142 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2023-179043

Published: 2023

Journal Articles

Chromatin Remodeler DEK Is a Sensor to Replication Stress and Contributes to HSC Defects in Fanconi Anemia

Zhe Chen, Feng Wu, Lei Li, Yan Li, Xueya Zhao, Yu Hou

Blood (2023) 142 (Supplement 1): 5670.

https://doi.org/10.1182/blood-2023-184605

Published: 2023

Journal Articles

RTK-RAS Signaling Pathway Was Enriched in Rare Acute Myeloid Leukemia Patients with t(16;21)(p11;q22)/ FUS::ERG

Anli Lai, Hui Wei, Ying Wang, Dong Lin, Chunlin Zhou, Bingcheng Liu, Runxia Gu, Yan Li, Shuning Wei, Benfa Gong, Kaiqi Liu, Xiaoyuan Gong, Yuntao Liu, Guangji Zhang, Junping Zhang, Yingchang Mi, Shaowei Qiu, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 5988.

https://doi.org/10.1182/blood-2023-179966

Published: 2023

Journal Articles

Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study

Blood (2023) 142 (Supplement 1): 827.

https://doi.org/10.1182/blood-2023-184421

Published: 2023

Journal Articles

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

Blood (2023) 142 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2023-184433

Published: 2023

Journal Articles

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

Chao-Ling Wan, Yuan-Hong Huang, Si-Man Huang, Tong-Tong Zhang, Kai-Wen Tan, Yan Qiu, Xiang-Dong Shen, Shuai-Shuai Ge, Han-Yu Cao, Yan-Yan Li, Songbai Liu, Qiao-Cheng Qiu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2023-185390

Published: 2023

Journal Articles

AURKA Kinase Controls Erythroblast Enucleation Via Regulation of Centrosome Localization and ECT2 Degradation

Yuanlin Xu, Yating Li, Wanxin Li, Yazhe Zhen, Peijun Jia, Yan Li, Jingxin Zhang, Huan Zhang, Jiaming Cao, Ying Zhang, Xinyang Zhao, Xiuli An, Shijie Zhang

Blood (2023) 142 (Supplement 1): 3834.

https://doi.org/10.1182/blood-2023-189444

Published: 2023

Journal Articles

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Yan-yan Li, Hai-xia Zhou, Si-man Huang, Chao-Ling Wan, Ming-zhu Xu, Wen-jie Gong, Chong-Sheng Qian, De-pei Wu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2023-185312

Published: 2023

Journal Articles

Hepatitis B Virus Infection Status and Reactivation Analysis in Multiple Myeloma in China

Wenjiao Tang, Xiang Liu, Yan Li, Li Zhang, Ting Niu

Blood (2023) 142 (Supplement 1): 6645.

https://doi.org/10.1182/blood-2023-186011

Published: 2023

Journal Articles

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Blood (2022) 140 (Supplement 1): 3609–3611.

https://doi.org/10.1182/blood-2022-158675

Published: 2022

Journal Articles

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 4045–4046.

https://doi.org/10.1182/blood-2022-155901

Published: 2022

Journal Articles

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Xing-yu Cao, Jian-Ping Zhang, Yan-Li Zhao, Min Xiong, Jiarui Zhou, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Xian Zhang, Junfang Yang, Peihua Lu

Blood (2022) 140 (Supplement 1): 4802–4803.

https://doi.org/10.1182/blood-2022-166993

Published: 2022

Journal Articles

Phase I Study of a Novel Oral Proteasome Inhibitor TQB3602 in Relapsed/Refractory Multiple Myeloma

Wenjiao Tang, Yan Li, Qiushi Liang, Ying Qu, Li Zhang, Yuzhang Liu, Baijun Fang, Zeng Yun, Xiaobo Du, Yaming Xi, Ting Wang, Xin Li, Jie Huang, Wenbin Qian, Zhen Cai, Qingwei Zhao, Yue Lv, Ting Niu

Blood (2022) 140 (Supplement 1): 4396–4397.

https://doi.org/10.1182/blood-2022-168091

Published: 2022

Journal Articles

FFA Promoting Proliferation and Migration Via Classical Wnt Signaling Pathway in Peripheral T Cell Lymphoma

Wei Guo, Xingtong Wang, Chunshui Liu, Yan Li, Ou Bai

Blood (2022) 140 (Supplement 1): 11506–11507.

https://doi.org/10.1182/blood-2022-170462

Published: 2022

Journal Articles

Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)

Congxiao Zhang, Runxia Gu, Chunlin Zhou, Yan Li, Yuntao Liu, Shuning Wei, Dong Lin, Benfa Gong, Kaiqi Liu, Qiuyun Fang, Xiaoyuan Gong, Shaowei Qiu, Bingcheng Liu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang

Blood (2022) 140 (Supplement 1): 2030–2032.

https://doi.org/10.1182/blood-2022-162459

Published: 2022

Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Blood (2022) 140 (Supplement 1): 203–204.

https://doi.org/10.1182/blood-2022-170698

Published: 2022

Journal Articles

The Clinical and Translational Exploration of the Role of S1P/SPHK1 Pathway in Non-Hodgkin Lymphoma with Obesity

Xingtong Wang, Wei Guo, Xiaoju Shi, Jia Li, Min Tan, Yan Li, Ou Bai

Blood (2022) 140 (Supplement 1): 9249–9250.

https://doi.org/10.1182/blood-2022-169371

Published: 2022

NARROW

Intracerebral Hemorrhage Leads to Anemia By Disrupting Erythropoiesis and Erythromyeloblastic Islands

The Impact of ZNF384 Rearranged on Antigen Editing during Treatment-Specific Selective Pressures in Adult B Cell Acute Lymphoid Leukemia

Prognostic Value of MRD By Flow Cytometry in Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Treated with Pediatric-Inspired Regimen: A Post-Hoc Analysis from a Prospective Study of China

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Chromatin Remodeler DEK Is a Sensor to Replication Stress and Contributes to HSC Defects in Fanconi Anemia

RTK-RAS Signaling Pathway Was Enriched in Rare Acute Myeloid Leukemia Patients with t(16;21)(p11;q22)/ FUS::ERG

Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

AURKA Kinase Controls Erythroblast Enucleation Via Regulation of Centrosome Localization and ECT2 Degradation

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Hepatitis B Virus Infection Status and Reactivation Analysis in Multiple Myeloma in China

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Phase I Study of a Novel Oral Proteasome Inhibitor TQB3602 in Relapsed/Refractory Multiple Myeloma

FFA Promoting Proliferation and Migration Via Classical Wnt Signaling Pathway in Peripheral T Cell Lymphoma

Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

The Clinical and Translational Exploration of the Role of S1P/SPHK1 Pathway in Non-Hodgkin Lymphoma with Obesity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only